Filtered By:
Source: Ontario Health Technology Assessment Series
Drug: Eloxatin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
CONCLUSIONS: KRAS status is predictive of outcomes in cetuximab and panitumumab monotherapy, and in cetuximab-irinotecan combination therapy. While KRAS testing is cost-effective for all strategies considered, it is not equally cost-effective for all treatment options.
PMID: 23074403 [PubMed]
Source: Ontario Health Technology Assessment Series - December 20, 2015 Category: Journals (General) Tags: Ont Health Technol Assess Ser Source Type: research
